Emcure Pharmaceuticals has been issued a Form 483 by the United States Food and Drug Administration (US FDA) following a current Good Manufacturing Practices (cGMP) inspection at its formulations facility in Sanand, Ahmedabad. The inspection, conducted from 6th May 2026 to 15th May 2026, resulted in seven procedural observations.
The company has stated that it is addressing these observations comprehensively and plans to respond to the US FDA within the stipulated timeframe. The inspection was part of the regulatory oversight to ensure compliance with manufacturing standards that protect public health by ensuring the safety, efficacy, and quality of drugs.
Form 483 is issued to a company at the conclusion of an inspection when investigators observe any conditions that may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts. The observations noted by the US FDA are procedural, indicating they may relate to documentation or processes rather than direct product quality issues.
Emcure Pharmaceuticals is committed to resolving these issues promptly to align with the regulatory requirements and maintain its manufacturing standards. The company has not disclosed the specific details of the observations but emphasised its dedication to compliance and quality assurance.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).